Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allo-APZ2-ACLF for Acute-on-Chronic Liver Failure
NCT03860155Phase 2Terminated
- Sponsor
- RHEACELL
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of EBESANAR in acute-on-chronic liver failure (ACLF), sponsored by RHEACELL. Started Mar 2019; status: terminated.
02
Drugs
EBESANAR
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT03860155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03860155.